Cerus Corporation Market Cap ($468.86 Million)
Market Cap & Net Worth: Cerus Corporation (CERS)
Cerus Corporation market cap. Cerus Corporation (NASDAQ:CERS) has a market capitalization of $468.86 Million ($468.86 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #12227 globally and #3087 in its home market, demonstrating a -1.27% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cerus Corporation's stock price $2.34 by its total outstanding shares 200368974 (200.37 Million). Also see Cerus Corporation operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Cerus Corporation Market Cap History (2015–2026)
Cerus Corporation market cap history from 2015 to 2026. Data shows change from $1.27 Billion to $468.86 Million (-5.90% CAGR). Check CERS stock price and chart for real-time trading data and today's change.
Index Memberships
Cerus Corporation is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.02% | #332 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #1229 of 3165 |
Weight: Cerus Corporation's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Cerus Corporation Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cerus Corporation's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Cerus Corporation equity growth rate to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
2.00x
Cerus Corporation's market cap is 2.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $871.61 Million | $37.18 Million | -$62.91 Million | 23.44x | N/A |
| 2017 | $677.25 Million | $43.57 Million | -$60.59 Million | 15.54x | N/A |
| 2018 | $1.02 Billion | $60.91 Million | -$57.56 Million | 16.68x | N/A |
| 2019 | $845.56 Million | $74.65 Million | -$71.24 Million | 11.33x | N/A |
| 2020 | $1.39 Billion | $91.92 Million | -$59.86 Million | 15.08x | N/A |
| 2021 | $1.36 Billion | $130.86 Million | -$54.38 Million | 10.43x | N/A |
| 2022 | $731.35 Million | $162.05 Million | -$42.83 Million | 4.51x | N/A |
| 2023 | $432.80 Million | $156.37 Million | -$37.49 Million | 2.77x | N/A |
| 2024 | $308.57 Million | $180.27 Million | -$20.92 Million | 1.71x | N/A |
| 2025 | $412.76 Million | $206.13 Million | -$15.63 Million | 2.00x | N/A |
Competitor Companies of CERS by Market Capitalization
Companies near Cerus Corporation in the global market cap rankings as of November 4, 2026. Also see balance sheet size of Cerus Corporation for a full breakdown of the balance sheet.
Key companies related to Cerus Corporation by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #110 globally with a market cap of $190.23 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #204 globally with a market cap of $119.12 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #226 globally with a market cap of $109.30 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #239 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #110 | Abbott Laboratories | NYSE:ABT | $190.23 Billion | $109.40 |
| #204 | Stryker Corporation | NYSE:SYK | $119.12 Billion | $310.55 |
| #226 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $98.88 |
| #239 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Market Capitalization of Cerus Corporation (2015–2026)
Market capitalization of Cerus Corporation from 2015 to today. Between 2015 and today, Cerus Corporation's market cap moved from $1.27 Billion to $ 468.86 Million, with a yearly change of -5.90%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $468.86 Million | +13.59% |
| 2025 | $412.76 Million | +33.77% |
| 2024 | $308.57 Million | -28.70% |
| 2023 | $432.80 Million | -40.82% |
| 2022 | $731.35 Million | -46.40% |
| 2021 | $1.36 Billion | -1.59% |
| 2020 | $1.39 Billion | +63.98% |
| 2019 | $845.56 Million | -16.77% |
| 2018 | $1.02 Billion | +50.00% |
| 2017 | $677.25 Million | -22.30% |
| 2016 | $871.61 Million | -31.17% |
| 2015 | $1.27 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Cerus Corporation was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $468.86 Million USD |
| MoneyControl | $468.86 Million USD |
| MarketWatch | $468.86 Million USD |
| marketcap.company | $468.86 Million USD |
| Reuters | $468.86 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cerus Corporation
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offer… Read more